ProbeSure™ OneStep RT-PCR Master Mix

Genotype directly from RNA samples. RNA reverse transcription and cDNA PCR genotyping simultaneously in a single, one-step reaction.

About

ProbeSure OneStep RT-PCR Master Mix combines reverse transcription (RT) and PCR in a single step. This advanced master mix simplifies workflows by eliminating the need for separate reactions for reverse transcription of RNA to cDNA, and PCR amplification from the newly generated cDNA.

ProbeSure OneStep RT-PCR Master Mix is highly efficient and sensitive, enabling detection of low-abundance RNA targets, particularly useful for applications such as gene expression analysis and viral RNA detection. ProbeSure OneStep RT-PCR Master Mix demonstrates robust performance across a wide range of RNA templates and can be employed for both routine and challenging samples.

FAQ:

What is OneStep RT-PCR?

A one-step RT-PCR (Reverse Transcription Polymerase Chain Reaction) allows for the amplification of a target DNA sequence directly from an RNA sample. It combines reverse transcription of RNA into complementary DNA (cDNA) and subsequent amplification of the target DNA sequence in a single reaction tube. Reverse transcription and cDNA amplification can also be carried out in two separate reactions (two-step method), but the one-step approach significantly improves and streamlines the workflow and reduces the risk of contamination.

What are the advantages of using a one-step RT-PCR over a two-step RT-PCR?

One-step RT-PCR combines reverse transcription of RNA into complementary DNA (cDNA) and subsequent amplification of the target DNA sequence in a single reaction tube. Reverse transcription and cDNA amplification can also be carried out in two separate reactions (two-step method), but the one-step approach significantly improves and streamlines the workflow and reduces the risk of contamination.

How does ProbeSure OneStep RT-PCR work?

ProbeSure OneStep RT-PCR Master Mix is designed for highly specific and sensitive one-step reverse transcriptase (RT) fluorescently-reporting PCR using RNA template.

The master mix includes optimised components which allow reverse transcription and subsequent PCR amplification to take place in the same reaction well. 

ProbeSure OneStep RT-PCR Master Mix may be used in endpoint or real-time modes.

The ProbeSure OneStep RT-PCR Master Mix reaction is comprised of two parts:

  • Assay mix comprising forward and reverse primers, and fluorogenic hydrolysis probes.
  • Universal ProbeSure OneStep RT-PCR Master Mix containing all the components required for reverse transcription and subsequent PCR.

When combined with template RNA, these components create a ProbeSure OneStep RT-PCR.

ProbeSure OneStep RT-PCR Master Mix is designed for use in PCR genotyping applications with hydrolysis probe-based assays.  It can be used with a variety of fluorogenic probe types including TaqMan®, ZEN™ probes and BHQ® / BHQplus® probes. 

Can ProbeSure OneStep RT-PCR Master Mix be used with different PCR instruments or platforms?

ProbeSure OneStep RT-PCR Master Mix can be used with any standard qPCR instrument, peltier or water bath-based thermal cycler.  The fluorescent data should be captured at the PCR endpoint at 40˚C or below. 

Do I need to use a specific reaction plate or reaction volume for ProbeSure OneStep RT-PCR Master Mix?

ProbeSure OneStep RT-PCR Master Mix can be used with any reaction plate or well volume. It is important that it is used at a final 1x concentration. 

Are there any specific precautions or considerations when using ProbeSure OneStep RT-PCR Master Mix?

When using the ProbeSure OneStep RT-PCR Master Mix, please keep in mind that RNA is highly susceptible to ubiquitous RNases.  Care should be taken when handling the samples. An empirical optimisation of RNA concentration should be carried out by testing a sample dilution range. If RNA samples contain EDTA, the concentration at the final reaction concentration should be no higher than 0.1 mM.

[fibosearch]
Name(Required)
This field is for validation purposes and should be left unchanged.

Contact us

MEET OUR TEAM

Steve Asquith Managing Director
Steve began his career in the Genetics Division of GlaxoSmithKline, as part of the team establishing GSK’s high-throughput core genotyping laboratory. Steve joined KBioscience when it was first founded in 2002 and was a key driver in taking the company from a small start-up to a multi-national service laboratory, quickly growing the company’s revenue to over $7.5M p.a. Following the acquisition of Kbioscience by LGC in 2011, Steve was appointed Global Director of Operations for LGC Genomics, responsible for over 100 staff in Europe and N. America, successfully elevating the genotyping products and service business. Steve held a crucial leadership role until he left in 2016. In 2017 Steve joined forces with John Holme to create 3CR Bioscience, a new company with a mission to deliver outstanding, customer-focused genotyping products with innovation and affordability at its core.
Dr. John Holme Technical Director
John joined KBioscience shortly after it was founded, in 2003, and became Head of Technical Development, building the company’s genotyping and DNA extraction product portfolio and service delivery until 2011 when it was acquired by LGC. Post-acquisition, John was appointed Head of Technical Group for LGC Genomics, in charge of all Research & Development and Technical Support activities for the company. In this role John continued to build on the high-quality products and services provided to the companies growing customer base. During the 19 years John has worked in commercial R&D, he has co-invented numerous highly successful products including PACE®, ProbeSure, KASP™, KlearKall, KlearGene, KlearAmp and KlearTaq™, creating breakthrough offerings in genotyping and extraction and generating huge revenues for the companies he has worked in. In 2017, he joined forces with Steve Asquith and started 3CR Bioscience. John is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Dr. Nisha JainOperations Director
Nisha has been innovating since the start of her career at Geneform Technologies developing Iso-thermal Genotyping Technologies. Nisha joined KBioscience in 2008, as Senior R&D Scientist and key account Technical Support Scientist, developing KASP and Klearkall performance and coinventing two further versions of KASP. Nisha has more than 15 years’ experience working in molecular biology and genotyping technologies, with extensive experience in the areas of R&D, Quality Assurance and Customer Technical Support. She has technically assisted many giants of the industry with their protocol development and troubleshooting and continues to deliver high-quality support and guidance. In 2018, Nisha joined 3CR Bioscience as Operations Director where she continues to develop PACE and ProbeSure for an increasing range of applications, and to grow 3CR Bioscience’s new product pipeline. Nisha is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Nazma Saffin General Manager
For 20 years Nazma Saffin has worked and gained extensive expertise within the genotyping sector. Working at Kbioscience and then LGC, she has held operational leadership posts responsible for manufacturing and laboratory services. With experience of ISO 9001 implementation, production scale up and LEAN operations, Nazma has successfully led highly profitable production departments. Joining 3CR Bioscience in 2022, Nazma is committed to delivering operational excellence.
Jon Curtis Non-Executive Chair
After 8 years in The Royal Air Force, Jon moved to the Imperial Cancer Research Fund where he pioneered the use of ultra high-throughput genomic automation, capable of 46,000 PCRs per hour. In the 1990’s Jon joined GlaxoSmithKline, implementing a high-throughput genomics platform into their drug discovery pipeline. Whilst there he also developed acoustic mixing into compound management, becoming the gold standard across pharma. Jon developed the world’s first commercially viable 1536-well PCR plates, automated thermal & laser plate-sealer, plus automated liquid-handling & tip washing tools to reduce waste and costs. In 2002 Jon co-founded KBioscience with Phil Robinson, utilising ultra high-throughput PCR instrumentation & a suite of automation tools to create the company’s SNPline robotic platform, with a capacity of 250,000 PCRs/day. The business was underpinned by their ground-breaking patented genotyping chemistry, KASP™, which has over 10,000 scientific papers to date. In November 2022 Jon joined 3CR Bioscience acting as an advisor bringing his commercial and scientific experience to the company.